Walking Speed: Japanese Data in Chronic Liver Diseases

Nishikawa, Hiroki; Enomoto, Hirayuki; Iwata, Yoshinori; Sakai, Yoshiyuki; Kishino, Kyohei; Ikeda, Naoto; Takashima, Tomoyuki; Aizawa, Nobuhiro; Takata, Ryo; Hasegawa, Kunihiro; Ishii, Noriko; Yuri, Yukihisa; Nishimura, Takashi; Iijima, Hiroko; Nishiguchi, Shuhei

doi:10.3390/jcm9010166

Cited by 7 publications

(6 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Management of edematous status in CLDs should be pivotal for avoiding GSL. In our previous investigation, we reported the significant negative correlation between ECW to TBW ratio and walking speed in patients with CLDs, which are similar to the current data (38). As shown in Figure 3, the stepwise decrease of ΔGS was found according to the liver disease severity.…”

Section: Discussionsupporting

confidence: 90%

Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases

Nishikawa

Enomoto

Ikeda

et al. 2021

In Vivo

Self Cite

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 90%

Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases

Nishikawa

Enomoto

Ikeda

et al. 2021

In Vivo

Self Cite

View full text Add to dashboard Cite

Section: Diagnostic Methods In the Field Of Sarcopeniamentioning

confidence: 99%

“…A walking speed/gait test is offered as a third option[ 2 , 32 ]. In a study by Nishikawa et al [ 32 ], a 6 m walking test was performed to measure muscle function in a group of patients with liver cirrhosis, with walking speed (WS) and gait speed (GS) defined, respectively. As a reference to define sarcopenia, bioelectrical impedance analysis (BIA) was used and therefore only patients without ascites were included.…”

Section: Diagnostic Methods In the Field Of Sarcopeniamentioning

confidence: 99%

See 1 more Smart Citation

Muscular abnormalities in liver cirrhosis

Hari

2021

WJG

View full text Add to dashboard Cite

Sarcopenia is becoming a well-established player in evaluating patients with chronic liver disease. Data regarding its clinical significance and consequences in the course of liver disease have been growing; many of the data support the idea that it impacts decompensation event frequency, prolonged hospitalization, and mortality, as well as providing the possibility to better prioritize patients on lists awaiting liver transplantation. When assessing the whole clinical scope of the field, which includes malnutrition and frailty, as well as the complete spectrum of muscle mass, strength, and function, it becomes clear that a well-founded approach in everyday clinical practice is essential. In this respect, this article attempts to unveil the most recently published data regarding possible methods and modalities that could be used to diagnose sarcopenia as early as possible, along with the required accuracy and reliability. From the most important field discoveries to data that need further clarification, the merits and weaknesses of the very diverse existing evaluation methods are presented. Finally, a critical overview is given, in an attempt to discern study lines of importance from those that could pose further ambiguity for the theme. The author also poses relevant questions that remain unanswered but are of clinical importance in the field.

show abstract

“…Additionally, SMIs of about 25% of patients younger than 65 years were below the reference values [ 30 ]. With regard to WS, only 17 (4.8%) of our 356 CLD patients had a WS below the initial AWGS criterion (0.8 m/s, the speed at which a person can manage to cross a crosswalk safely) [ 34 ], indicating that WS may not be suitable as an initial screening for sarcopenia [ 35 ]. These results do not deny the usefulness of measuring WS as an indicator of physical function.…”

Section: Jsh Guidelines For Sarcopenia In Liver Disease and Japan Evidence-based Clinical Practice Guidelines For Liver Cirrhosis 2020 (3mentioning

confidence: 99%

Sarcopenia and Frailty in Liver Cirrhosis

Nishikawa

Fukunishi

Asai

et al. 2021

Life

Self Cite

View full text Add to dashboard Cite

Skeletal muscle is the largest organ in the body, and skeletal muscle atrophy results from a shift in the balance of protein synthesis and degradation toward protein breakdown. Primary sarcopenia is defined as a loss of skeletal muscle mass and strength or physical function due to aging, and secondary sarcopenia is defined as a loss of skeletal muscle mass and strength or physical function due to underlying diseases. Liver cirrhosis (LC) is one of the representative diseases which can be complicated with secondary sarcopenia. Muscle mass loss becomes more pronounced with worsening liver reserve in LC patients. While frailty encompasses a state of increased vulnerability to environmental factors, there is also the reversibility of returning to a healthy state with appropriate intervention. Several assessment criteria for sarcopenia and frailty were proposed in recent years. In 2016, the Japan Society of Hepatology created assessment criteria for sarcopenia in liver disease. In Japan, health checkups for frailty in the elderly aged 75 years or more started in April 2020. Both sarcopenia and frailty can be adverse predictors for cirrhotic patients. In this review article, we will summarize the current knowledge of sarcopenia and frailty in LC patients.

show abstract

Walking Speed: Japanese Data in Chronic Liver Diseases

Cited by 7 publications

References 40 publications

Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases

Predictors for Grip Strength Loss in Patients With Chronic Liver Diseases

Muscular abnormalities in liver cirrhosis

Sarcopenia and Frailty in Liver Cirrhosis

Contact Info

Product

Resources

About